Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.9800 (-2.56%) ($7.8400 - $8.0500) on Fri. Nov. 6, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.43% (three month average) | RSI | 37 | Latest Price | $7.9800(-2.56%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1% a day on average for past five trading days. | Weekly Trend | HTBX declines -0.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(33%) ARKK(32%) XBI(32%) BLOK(31%) IBB(30%) | Factors Impacting HTBX price | HTBX will decline at least -3.215% in a week (0% probabilities). VXX(-19%) VIXM(-18%) UUP(-15%) XLU(-4%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.215% (StdDev 6.43%) | Hourly BBV | 0.4 () | Intraday Trend | -0.9% | | | |
|
1 - 5 Day Possible Target | $-1.97(-124.69%) | Resistance Level | $8.45 | 5 Day Moving Average | $8.19(-2.56%) | 10 Day Moving Average | $8.22(-2.92%) | 20 Day Moving Average | $8.45(-5.56%) | To recent high | -47.5% | To recent low | 11.8% | Market Cap | $878m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |